373 related articles for article (PubMed ID: 30978462)
1. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.
Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C
J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462
[TBL] [Abstract][Full Text] [Related]
2. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.
Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD
PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028
[TBL] [Abstract][Full Text] [Related]
3. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
[TBL] [Abstract][Full Text] [Related]
4. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
Oberacher H; Arnhard K; Linhart C; Diwo A; Marksteiner J; Humpel C
J Alzheimers Dis; 2017; 57(2):493-504. PubMed ID: 28269764
[TBL] [Abstract][Full Text] [Related]
5. High-resolution metabolomic profiling of Alzheimer's disease in plasma.
Niedzwiecki MM; Walker DI; Howell JC; Watts KD; Jones DP; Miller GW; Hu WT
Ann Clin Transl Neurol; 2020 Jan; 7(1):36-45. PubMed ID: 31828981
[TBL] [Abstract][Full Text] [Related]
6. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples.
Milos T; Rojo D; Nedic Erjavec G; Konjevod M; Tudor L; Vuic B; Svob Strac D; Uzun S; Mimica N; Kozumplik O; Barbas C; Zarkovic N; Pivac N; Nikolac Perkovic M
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Dec; 127():110830. PubMed ID: 37454721
[TBL] [Abstract][Full Text] [Related]
8. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
[TBL] [Abstract][Full Text] [Related]
9. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
[TBL] [Abstract][Full Text] [Related]
10. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
[TBL] [Abstract][Full Text] [Related]
11. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
Liu Y; Li N; Zhou L; Li Q; Li W
Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
[TBL] [Abstract][Full Text] [Related]
12. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer's Disease.
Huang YL; Lin CH; Tsai TH; Huang CH; Li JL; Chen LK; Li CH; Tsai TF; Wang PN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681563
[TBL] [Abstract][Full Text] [Related]
14. Identifying Hair Biomarker Candidates for Alzheimer's Disease Using Three High Resolution Mass Spectrometry-Based Untargeted Metabolomics Strategies.
Chang CW; Hsu JY; Hsiao PZ; Chen YC; Liao PC
J Am Soc Mass Spectrom; 2023 Apr; 34(4):550-561. PubMed ID: 36973238
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.
González-Domínguez R; García A; García-Barrera T; Barbas C; Gómez-Ariza JL
Electrophoresis; 2014 Dec; 35(23):3321-30. PubMed ID: 25136972
[TBL] [Abstract][Full Text] [Related]
16. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment.
González-Domínguez R; Rupérez FJ; García-Barrera T; Barbas C; Gómez-Ariza JL
Curr Alzheimer Res; 2016; 13(6):641-53. PubMed ID: 26825096
[TBL] [Abstract][Full Text] [Related]
19. A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease.
Lin CN; Huang CC; Huang KL; Lin KJ; Yen TC; Kuo HC
Ann Clin Transl Neurol; 2019 Mar; 6(3):537-545. PubMed ID: 30911577
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
